Please login to the form below

Not currently logged in

Novartis makes case for gene therapy Zolgensma in SMA

Novartis HQNew data revealed ahead of FDA review

Gilead drives NASH development with insitro collaboration

GileadAnnouncement comes days after Novo Nordisk deal

Catalent preps for complex therapy boom with $1.2bn Paragon buy

CatalentReflects growing investment in cell and gene therapies

First-in-class hepatitis B/D drug raises cure hope

Those taking the regimen saw virus levels decline

J&J’s Invokana first SGLT2 to show kidney disease benefits

Could help revival after amputation risk scare

Promethera’s liver failure stem cell therapy clears first hurdle

PromotheraTechnique could be alternative to transplant

CAR-T player Autolus seeks $100m from follow-on financing

AutolusFunds will further develop pipeline

Novo Nordisk and Gilead join forces in NASH

Novo Nordisk headquartersWill combine semaglutide with Gilead’s cilofexor and firsocostat

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...